Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Dyadic International, Inc.NASDAQ: DYAI

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $139.3K fell 38.1% year over year, behind the -19.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 27.6% from the prior quarter. Over 3 fiscal years it compounded at -21.0% a year.

Context

  • Stock-based compensation amounted to 75.5% of revenue in FY2025, up 43.3 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -38.1% toward the trailing-twelve-month pace of -19.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$139.3K-27.6% QoQ
Last fiscal yearDec 2025
$930.18K-17.4% YoY
LTMMar 2026
$844.45K-19.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.1%——
1 year-17.4%——
3-year CAGR-21.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
930.18K USD
Year-over-year change
-17.4%
4-year CAGR
-15.0%

Stock-Based Compensation vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.2% is the 5th highest of 7, against a peer median of -0.2%.
  • Stock-based compensation amounts to 28.4% of revenue for DYAI, versus a peer median of 39.1%.
DYAI Competitors
Stock-Based Compensation for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$10.38M USD-11.5%-13.2%39.1%
VERUVeru Inc.LTM Mar 2026$4.36M USD-62.1%-10.3%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$2.91M USD+50.5%+4.3%—
ANVSAnnovis Bio, Inc.LTM Mar 2026$1.48M USD-62.7%+481.3%—
RNXTRenovoRx, Inc.LTM Mar 2026$1.3M USD+24.7%+25.3%87.0%
ATHEAlterity Therapeutics LimitedFY2025A$979.92K AUD+11.1%-13.3%18.0%
DYAIDyadic International, Inc.LTM Mar 2026$844.45K USD-19.2%-21.0%28.4%
PYPDPolyPid Ltd.LTM Dec 2025$0 USD———
Peer median (excluding DYAI) —-0.2%-3.0%39.1%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Depreciation & Amortization0000(24.17K)
Deferred Income Tax00000
Stock-Based Compensation1.78M1.89M1.24M1.13M930.18K
Change in Working Capital1.19M(321.17K)(143.21K)754.53K660.8K
Accounts Receivables(13.92K)(47.18K)(93.13K)205.26K(857.85K)
Inventory00000
Accounts Payables549.56K(248.13K)(651.17K)(180.18K)314.45K
Other Working Capital652.59K(25.87K)601.09K729.45K1.2M
Other Non-Cash Items(1.18M)83.71K(1.03M)(46.45K)95.6K
Operating Cash Flow(11.28M)(8.08M)(6.73M)(3.97M)(5.7M)
Capital Expenditures000(4)0
Acquisitions (Net)00000
Purchases of Investments(11.28M)(9.87M)(3M)(7.34M)(5.95M)
Sales of Investments16.51M7.5M10.45M5.47M6.03M
Other Investing Activities00000
Investing Cash Flow5.22M(2.37M)7.45M(1.88M)82.09K
Debt Repayment0005.82M0
Common Stock Issued00024.25K4.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.23M543.59K000
Financing Cash Flow1.23M543.59K05.85M4.96M
Effect of Forex Changes(63.26K)(44.74K)(2.39K)(5.8K)1.94K
Net Change in Cash(4.89M)(9.95M)720.76K(8.28K)(653.25K)
Free Cash Flow(11.28M)(8.08M)(6.73M)(3.97M)(5.7M)

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.